These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24993601)

  • 21. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
    Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skin ulcers related to chronic graft-versus-host disease: clinical findings and associated morbidity.
    Jachiet M; de Masson A; Peffault de Latour R; Rybojad M; Robin M; Bourhis JH; Xhaard A; Dhedin N; Sicre de Fontbrune F; Suarez F; Barete S; Parquet N; Nguyen S; Ades L; Rubio MT; Wittnebel S; Bagot M; Socié G; Bouaziz JD
    Br J Dermatol; 2014 Jul; 171(1):63-8. PubMed ID: 24404963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Partial reconstitution of cutaneous microvessels in long-term survivors after allogeneic bone marrow transplantation.
    Haeusermann P; Kump E; Rovó A; Tichelli A; Itin P; Gratwohl A; Biedermann BC
    Dermatology; 2009; 219(1):32-41. PubMed ID: 19407437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial.
    Flowers ME; Parker PM; Johnston LJ; Matos AV; Storer B; Bensinger WI; Storb R; Appelbaum FR; Forman SJ; Blume KG; Martin PJ
    Blood; 2002 Jul; 100(2):415-9. PubMed ID: 12091330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation.
    Bensinger WI; Clift R; Martin P; Appelbaum FR; Demirer T; Gooley T; Lilleby K; Rowley S; Sanders J; Storb R; Buckner CD
    Blood; 1996 Oct; 88(7):2794-800. PubMed ID: 8839878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical manifestations of graft-versus-host disease.
    Cornejo CM; Kim EJ; Rosenbach M; Micheletti RG
    J Am Acad Dermatol; 2015 Apr; 72(4):690-5. PubMed ID: 25641626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unusual presentations of chronic graft versus host disease.
    Okorie CL; Salem I; Scripture AJ; Simmons BJ; Momtahen S; Yan S
    J Cutan Pathol; 2024 Jan; 51(1):15-19. PubMed ID: 37150830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases.
    Janin A; Socie G; Devergie A; Aractingi S; Esperou H; Vérola O; Gluckman E
    Ann Intern Med; 1994 Jun; 120(12):993-8. PubMed ID: 8185148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease.
    Cardones AR; Sullivan KM; Green C; Chao NJ; Rowe-Nichols K; Bañez LL; Burton CS; Horwitz ME; Long GD; Rao CL; Sarantopoulos S; Sidhu-Malik N; Sung AD; Hall RP
    JAMA Dermatol; 2019 Jul; 155(7):833-837. PubMed ID: 30994873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in protein serum levels during stem cell transplantation.
    Metafuni E; Giammarco S; De Ritis DG; Rossi M; Corrente F; Piccirillo N; Bacigalupo AP; Sica S; Chiusolo P
    Eur J Clin Invest; 2017 Oct; 47(10):711-718. PubMed ID: 28796281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation.
    Tseng LH; Lin MT; Hansen JA; Gooley T; Pei J; Smith AG; Martin EG; Petersdorf EW; Martin PJ
    Blood; 1999 Oct; 94(8):2911-4. PubMed ID: 10515896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantation.
    Hidaka D; Hayase E; Shiratori S; Hasegawa Y; Ishio T; Tateno T; Okada K; Goto H; Sugita J; Onozawa M; Nakagawa M; Kahata K; Endo T; Hashimoto D; Teshima T
    Clin Transplant; 2018 Sep; 32(9):e13361. PubMed ID: 30054935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
    Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressings in two bone marrow transplant recipients with cutaneous graft-versus-host disease.
    Olson KA; West K; McCarthy PL
    Pharmacotherapy; 2014 Jun; 34(6):e60-4. PubMed ID: 24700567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease.
    Sorenson E; McAndrew R; Patel V; Logan AC; Koo J; Levin E
    JAMA Dermatol; 2015 Jun; 151(6):635-7. PubMed ID: 25806783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
    Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
    Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.